STOCKHOLDERS' DEFICIT (Details) - Equity Option [Member] - $ / shares |
6 Months Ended | 12 Months Ended | |
|---|---|---|---|
Jun. 30, 2026 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Offsetting Assets [Line Items] | |||
| Number of shares outstanding, Beginning balance | 1,000,000 | 1,000,000 | |
| Weighted average exercise price outstanding, Beginning balance | $ 0.3600 | $ 0.3600 | |
| Weighted average remaining contractual life, outstanding | 5 months 1 day | 11 months 4 days | |
| Number of shares, Issued | 0 | 0 | |
| Weighted average exercise price, issued | $ 0 | $ 0 | |
| Number of shares, exercised | 0 | 0 | |
| Weighted average exercise price, exercised | $ 0 | $ 0 | |
| Number of shares, cancelled | (1,000,000) | 0 | |
| Weighted average exercise price, cancelled | $ 0 | $ 0 | |
| Number of shares outstanding, Ending balance | 0 | 1,000,000 | 1,000,000 |
| Weighted average exercise price outstanding, Ending balance | $ 0 | $ 0.3600 | $ 0.3600 |
| Number of shares, exercisable | 0 | ||
| Weighted average exercise price, exercisable | $ 0 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|